M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy PharmaphorumNovo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence.NeuroscienceRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) Pharmaphorum Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence. Neuroscience Read full story Post navigation Previous: Third Circuit Affirms Denial of Stelara Biosimilar InjunctionNext: Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026